Advancing psoriasis research requires thinking more broadly about the challenges that continue to shape psoriasis research and what sponsors should consider when designing the next generation of psoriasis studies.

KEY TAKEAWAY: The gaps that leave patients undiagnosed, undertreated, and underrepresented also make psoriasis trials harder to enroll, harder to assess consistently, and harder to generalize.

Psoriasis is far more than a skin condition. It is a chronic, immune-mediated inflammatory disease affecting more than 8 million people in the United States and an estimated 125 million people worldwide.1 In recognition of its global burden, the World Health Organization formally identified psoriasis as a serious noncommunicable disease requiring greater awareness and action.7

Public awareness has improved considerably. Yet awareness alone does not eliminate the barriers that continue to affect both patients and the clinical trials designed to develop better therapies. Delayed diagnosis, undertreatment, and inequities in care do not end in the clinic. They reappear downstream in clinical research, influencing patient identification, disease assessment, enrollment, and ultimately the quality of the evidence used to guide treatment decisions.

The Awareness Gap Is Also a Diagnostic Gap

The awareness gap surrounding psoriasis is also a diagnostic gap. Psoriasis is a systemic inflammatory disease, and one of its most significant comorbidities often goes unrecognized. Psoriatic arthritis develops in a substantial proportion of patients, and skin involvement precedes joint disease in roughly 84% of cases, placing dermatologists on the front line of early detection. Yet a meta-analysis of dermatology clinic populations found a pooled prevalence of undiagnosed psoriatic arthritis of 15.5%, with individual studies reporting rates as high as 29% to 41%.2 Joint damage that occurs during those diagnostic delays is irreversible.

Those challenges become even more pronounced in patients with skin of color. Diagnosis of psoriasis relies heavily on erythema, yet the classic pink-to-red plaques familiar from textbooks often appear violaceous, gray, or brown in darker skin phototypes.5,6 Thick scale may further obscure the underlying color, increasing the potential for missed or delayed diagnosis. The consequences are well documented: later diagnosis, more severe disease at presentation, and higher rates of misdiagnosis in populations that have historically been underrepresented in dermatology research.

Where That Gap Reappears in Clinical Trials

The same diagnostic and representation gaps that affect patient care do not disappear once a patient enters a clinical trial. They reappear as operational challenges that influence enrollment, disease assessment, and ultimately the quality of the evidence sponsors rely on.

Today, many operational challenges in psoriasis trials extend beyond simply finding patients.

  • Primary efficacy endpoints remain investigator-scored and inherently subjective. PASI combines erythema, induration, and desquamation across four body regions, each graded visually by the investigator. Reliability studies have consistently demonstrated meaningful inter-rater variability, and investigator experience measurably improves scoring consistency.3,4
  • The erythema component is least reliable in patients with darker skin phototypes, introducing potential measurement bias where representation is already limited.
  • Despite growing emphasis on diversity in clinical research, representation remains limited, particularly among Black and Latino participants in pivotal psoriasis trials.
  • Biologic-naive patients are becoming increasingly difficult to identify, making realistic screening and washout strategies essential. Sites without well-established psoriasis patient populations often experience this challenge first.

What That Means for Site Selection

For sponsors, these realities shift the conversation from simply identifying sites that can enroll quickly to selecting sites that can enroll the right patients, evaluate disease consistently, and generate reliable endpoint data. Operational experience becomes just as important as patient access.

Sponsors should look for research sites and investigator networks that demonstrate:

  • Dermatology investigators trained to a standardized, calibrated PASI and IGA assessment methodology rather than practices that use these scales only occasionally.
  • Experience evaluating psoriasis across the full spectrum of skin phototypes, including recognition of non-erythematous plaque presentation and post-inflammatory pigment change.
  • Access to diverse, trial-ready psoriasis populations, including biologic-naive patients, rather than relying on broad dermatology panels that require extensive rescreening.
  • Realistic screening and washout strategies, supported by patient retention practices that keep participants engaged during periods when disease control may be intentionally interrupted.
  • Consistent scoring discipline across every site within the network, ensuring that patients are assessed consistently regardless of location.

HOW PRECEFI SUPPORTS PSORIASIS RESEARCH

Psoriasis research demands more than access to patients. It requires investigators who routinely evaluate plaque psoriasis, understand how disease presentation varies across skin types, and apply standardized severity assessments with consistency across every study visit.

Precefi’s dermatology research network is built specifically around these operational challenges. Rather than assembling sites study by study, Precefi’s network is built on long-standing relationships with experienced dermatology investigators who routinely participate in psoriasis research.

Our investigators are supported by standardized training, consistent study execution, and operational processes designed to reduce variability across sites.

Through a coordinated U.S. and Latin American network, Precefi helps sponsors execute psoriasis studies with experienced dermatology investigators, streamlined startup through our “1 Contract, 1 Price” model, and access to diverse patient populations that more accurately reflect the people living with psoriasis.

The result is a research network designed to generate high-quality, consistent endpoint data while supporting reliable enrollment and operational excellence throughout study execution.

Conclusion

Closing the gaps in diagnosis, representation, and disease assessment leads to better clinical research and better evidence for the millions of people living with psoriasis.

Advancing psoriasis research requires experienced investigators, consistent execution, and clinical trial networks capable of generating evidence that truly reflects the patients these therapies are intended to serve.

References

  1. National Psoriasis Foundation. Psoriasis Action Month. Accessed August 2026. https://www.psoriasis.org/psoriasis-action-month
  2. Villani AP, Rouzaud M, Sevrain M, et al. Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: systematic review and meta-analysis. J Am Acad Dermatol. 2015;73(2):242-248. doi:10.1016/j.jaad.2015.05.001
  3. Berth-Jones J, Grotzinger K, Rainville C, et al. A study examining inter- and intra-rater reliability of three scales for measuring severity of psoriasis: Psoriasis Area and Severity Index, Physician’s Global Assessment and Lattice System Physician’s Global Assessment. Br J Dermatol. 2006;155(4):707-713. doi:10.1111/j.1365-2133.2006.07389.x
  4. Fink C, Alt C, Uhlmann L, Klose C, Enk A, Haenssle HA. Intra- and interobserver variability of image-based PASI assessments in 120 patients suffering from plaque-type psoriasis. J Eur Acad Dermatol Venereol. 2018;32(8):1314-1319. doi:10.1111/jdv.14960
  5. Gkini MA, Alexis AF, et al. Psoriasis in people with skin of color: an evidence-based update. Int J Dermatol. 2025. doi:10.1111/ijd.17651
  6. Psoriasis in skin of color: clinical presentation, diagnostic challenges, and therapeutic considerations. An Bras Dermatol. 2026. doi:10.1016/j.abd.2026.03.004
  7. World Health Organization. Global Report on Psoriasis. Geneva: World Health Organization; 2016.